Chemoenzymatic Synthesis and Antiherpes Activity of 5-Substituted 4,6-Difluorobenzimidazoles Ribo- and 2′-Deoxyribonucleosides

Abstract

A series of 5,6-disubstituted benzimidazole nucleosides, obtained earlier, did not show any significant antiviral activity at relatively low cytotoxicity in vitro. In the course of our research we have succeeded in introducing an additional fluorine atom into the benzimidazole ring system. A new series of 4,6-difluorobenzimidazoles, bearing various groups (fluoro-, methoxy-, ethoxy-, morpholino-, and pyrrolidino-) in the 5-position of the benzene ring, have been synthesized. All these compounds proved to be substrates for recombinant E. coli purine nucleoside phosphorylase (PNP) in the transglycosylation reaction. Effective methods for the synthesis of ribo- and 2′-deoxyribonucleosides with high yields (60–90%) have been described, and the formation of regioisomeric N3-nucleosides of benzimidazoles have been detected. The biological activity of the nucleosides obtained against herpes simplex virus type 1 (HSV-1) has been elucidated. All compounds show a low cytotoxicity in the cell culture Vero E6. 4,5,6-Trifluoro-1-(β-d-ribofuranosyl)benzimidazole and 5-methoxy-4,6-difluoro-1-(β-d-2′-deoxyribofuranosyl)benzimidazole proved to inhibit completely the progression of the virus cytopathic effect (CPE) at a multiplicity of infection (MOI) of 0.01 PFU/cell.

Key words

drug discovery - herpes simplex virus - fluorine - nucleosides

• References

• 1 Galmarini CM, Popowycz F, Joseph B. Curr. Med. Chem. 2008; 15: 1072
• 2 Biron KK. Antiviral Res. 2006; 71: 154
• 3 De Clercq E. Adv. Virus Res. 2009; 73: 1
• 4 Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith III AA, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW. Antimicrob. Agents Chemother. 2002; 46: 2365
• 5 Hwang JS, Schilf R, Drach JC, Townsend LB, Bogner E. Antimicrob. Agents Chemother. 2009; 53: 5095
• 6 Prichard MN, Frederick SL, Daily S, Borysko KZ, Townsend LB, Drach JC, Kern ER. Antimicrob. Agents Chemother. 2011; 55: 2442
• 7 Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB. Antimicrob. Agents Chemother. 2003; 47: 2186
• 8 Krosky PM, Borysko KZ. Antimicrob. Agents Chemother. 2002; 2: 478
• 9 Averyl RK, Marty FM, Strasfeld L, Lee I, Arrieta A, Chou S, Tatarowicz W, Villano S. Transplant Infect. Dis. 2010; 12: 489
• 10 Trofe J, Pote L, Wade E, Blumberg E, Bloom RD. Ann. Pharmacother. 2008; 42: 1447
• 11 Alain S, Revest M, Veyer D, Essig M, Rerollers JP. Transplant. Proc. 2013; 45: 1603
• 12 Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L. Lancet Infect. Dis. 2011; 11: 284
• 13 Drugs in R & D 2007; 8: 188 ; DOI: 10.2165/00126839-200708030-00006
• 14 Konstantinova ID, Selezneva OM, Fateev IV, Balashova TA, Kotovskaya SK, Baskakova ZM, Charushin VN, Baranovsky AV, Miroshnikov AI, Balzarini J, Mikhailopulo IA. Synthesis 2013; 45: 272
• 15 Budow S, Kozlowska M, Gorska A, Kazimierczuk Z, Eickmeier H, Colla P, Gosselin G, Seela F. ARKIVOC 2009; (iii): 225
• 16 Hood MA, Finley RS. DICP, Ann. Pharmacother. 1991; 25: 518
• 17 Mikhailopulo IA. Curr. Org. Chem. 2007; 11: 317
• 18 Mikhailopulo IA, Zinchenko AI, Bokut SB, Dudchik NV, Barai VN, Kalinichenko EN, Rosemeyer H, Seela F. Biotechnol. Lett. 1992; 14: 885
• 19 Mikhailopulo IA, Miroshnikov AI. Acta Naturae 2010; 2: 36
• 20 Bzowska A, Kulikowska E, Shugar D. Pharmacol. Ther. 2000; 88: 349
• 21 Finger GC, Reed FH, Finnerty JF. J. Am. Chem. Soc. 1951; 73: 153
• 22 Montgomery JA, Hewson K. J. Med. Chem. 1965; 8: 737
• 23 Keana JF, Kher SM, Cai SX, Dinsmore CM, Glenn AG, Guastella J, Huang JC, Ilyin V, Lu Y, Mouser PL, Woodward RM, Weber E. J. Med. Chem. 1995; 38: 4367
• 24 Natesan S, Mohammed AR (Dr Reddys Lab Ltd) PCT Int. Appl WO 2004/037765, 2004
• 25 Leyva S, Castanedo V, Leyva E. J. Fluorine Chem. 2003; 121
• 26 Drach JK, Townsend LB, Boyd FL, Chamberlain SD, Daluge S, Deaton D, Andersen M, Freeman G. US 2002/0094963 A1, 2002
• 27 Nixon AE, Hunter JL, Bonifacio G, Eccleston J, Webb MR. Anal. Biochem. 1998; 265: 299
• 28 Koellner G, Bzowska A, Wielgus-Kutrowska B, Luic M, Steiner T, Saenger W, Stepinski J. J. Mol. Biol. 2002; 315: 351
• 29 Fateev IV, Kharitonova MI, Antonov KV, Konstantinova ID, Stepanenko VN, Esipov RS, Seela F, Temburnikar KW, Seley-Radtke KL, Stepchenko VA, Sokolov YA, Miroshnikov AI, Mikhailopulo IA. Chem. Eur. J. 2015; 25: 13401
• 30 Esipov RS, Gurevich AI, Chuvikovsky DV, Chupova LA, Muravyova TI, Miroshnikov AI. Protein Expression Purif. 2002; 24: 56
• 31 De Clercq E, Descamps J, Verheist G, Walker RT, Jones AS, Torrence PF. J. Infect Dis. 1980; 141: 563
• 32 Fedorov II, Kazmina EM, Gurskaya GV, Jasko MV, Zavodnic VE, Balzarini J, De Clercq E, Faraj A, Sommadossi JP, Imbach JL, Gosselin G, Novel J. Med. Chem. 1997; 40: 486
• 33 Petrera E, Níttolo AG, Alché LE. BioMed Res. Int. 2014; Article ID 947560
• 34 Holý A, De Clercq E, Votruba I In Nucleotide Analogues as Antiviral Agents, Proceedings of Symposium on Nucleoside Analogues as Antiviral Agents, 196th National Meeting of the ACS, Los Angeles, CA (USA), 25–30 September 1988. Martin JC. American Chemical Society; Washington DC: 1989: 51-71
• 35 Selvam P, Lakra DR, Pannecouque C, De Clercq E. Indian J. Pharm. Sci. 2012; 74: 275
• 36 Galegov GA, Shobukhov VM, Leont’eva NA, Yas’ko MV. Russ. J. Bioorg. Chem. 1997; 1: 906
• 37 Andronova VL, Skorobogatyi MV, Manasova EV, Berlin YuA, Korshun VA, Galegov GA. Russ. J. Bioorg. Chem. 2003; 29: 262